Pacific Edge

Products in development and in clinical trials are accurate and simple to use genomic and proteomic tools for the earlier detection, improved characterization and better management of gastric, bladder, colorectal, and endometrial cancers and melanoma.

The company has recently completed and released its first product for the detection of bladder cancer. Cxbladder is a non-invasive, accurate test that enables the early detection of bladder cancer from a small volume of urine, providing general practitioners and urologists with a quick, cost effective and accurate measure of the presence of the cancer. Cxbladder provides urologists with the opportunity to reduce their reliance on the need for invasive tests such as cystoscopy.

Pacific Edge's potential product benefits are compelling to patients and clinicians as they seek to address a number of important shortcomings in current disease detection and management, including the need for earlier detection, better characterization, lower cost, non-invasive technology, and greater accuracy.

The company is commercializing its products from its new diagnostic laboratory in New Zealand and plans further commercialization in the US and Europe as a centralized diagnostic service through its own facilities or as a turn-key solution licensed to selected partners.

Pacific Edge has plans for further studies in key markets to engage leading medical and urological opinion leaders who will be vital to success in new markets.

Website: http://www.peblnz.com/

The company profiled is one of the investment opportunities currently available in New Zealand. Please note that these opportunities are not endorsed or recommended by New Zealand Trade and Enterprise (NZTE) and may be updated from time to time. Investors are advised to contact our New Zealand-based Investment Specialist to discuss further and to conduct their own due diligence and independent advice on the relevant investment, before committing to any investment.